Corcept Therapeutics Newsroom

Corcept Therapeutics Presents Phase 3 Long-Term Extension Study Of Relacorilant Demonstrated Durable Cardiometabolic Improvements In Patients With Hypercortisolism

BenzingaDec 16 21:04

Express News | Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients With Hypercortisolism

BreakingsDec 16 21:00

Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating

Futu NewsDec 13 20:33 · Ratings

Corcept Therapeutics (CORT) Receives a Buy From Truist Financial

TipRanksDec 13 20:16 · Ratings

Corcept Announces Primary Endpoint Met In Treatment Phase Of CATALYST Trial In Patients With Hypercortisolism And Difficult-To-Control Diabetes

BenzingaDec 13 05:09

Express News | Corcept Therapeutics Inc - Korlym Safety Profile Consistent With Label, No New Side Effects

BreakingsDec 13 05:05

Express News | Corcept Announces Positive Results in Treatment Phase of Catalyst Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes

BreakingsDec 13 05:05

CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study

Zacks Dec 12 22:35

Sector Update: Health Care Stocks Mixed Pre-Bell Thursday

MT NewswiresDec 12 22:07

Optimistic Outlook for Corcept Therapeutics Amid Promising Developments and Regulatory Advantages

TipRanksDec 12 19:55

Correction to Corcept Therapeutics Shares Fall Article

Dow JonesDec 12 06:02

Corcept Therapeutics Fall 7% After ALS Drug Fails Trial

WSJDec 12 05:49

Express News | Corcept Therapeutics Inc - Dazucorilant Patients Experienced More Gastrointestinal Upset Than Placebo

BreakingsDec 12 05:10

Corcept Announces Results From Phase 2 Study Of Dazucorilant In Patients With Amyotrophic Lateral Sclerosis; DAZALS Did Not Meet Its Primary Endpoint, Which Was The Change From Baseline In The ALS Functional Rating Scale-Revised In Patients Who...

BenzingaDec 12 05:08

Express News | Corcept Therapeutics Inc - Long-Term Extension Study to Assess Overall Survival in March 2025

BreakingsDec 12 05:07

Express News | Corcept Therapeutics Inc - No Deaths in 300 Mg Arm, 5 Deaths in Placebo Group

BreakingsDec 12 05:06

Express News | Corcept Therapeutics Inc - Dazals Study Did Not Meet Primary Endpoint

BreakingsDec 12 05:06

Express News | Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)

BreakingsDec 12 05:05

S&P 500 Futures Rise In Premarket Trading; Bausch + Lomb, Bio-Techne Lag

Dow JonesDec 11 20:30

Corcept (CORT) Is an Incredible Growth Stock: 3 Reasons Why

Zacks Dec 10 01:00